TITLE

A PBPK Modeling-Based Approach to Account for Interactions in the Health Risk Assessment of Chemical Mixtures

AUTHOR(S)
Haddad, Sami; Béliveau, Martin; Tardif, Robert; Krishnan, Kannan
PUB. DATE
September 2001
SOURCE
Toxicological Sciences;Sep2001, Vol. 63 Issue 1, p125
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The objectives of the present study were: (1) to develop a risk assessment methodology for chemical mixtures that accounts for pharmacokinetic interactions among components, and (2) to apply this methodology to assess the health risk associated with occupational inhalation exposure to airborne mixtures of dichloromethane, benzene, toluene, ethylbenzene, and m-xylene. The basis of the proposed risk assessment methodology relates to the characterization of the change in tissue dose metrics (e.g., area under the concentration-time curve for parent chemical in tissues [AUCtissue], maximal concentration of parent chemical or metabolite [Cmax], quantity metabolized over a period of time) in humans, during mixed exposures using PBPK models. For systemic toxicants, an interaction-based hazard index was calculated using data on tissue dose of mixture constituents. Initially, the AUCtarget tissue (AUCtt) corresponding to guideline values (e.g., threshold limit value [TLV]) of individual chemicals were obtained. Then, the AUCtt for each chemical during mixed exposure was obtained using a mixture PBPK model that accounted for the binary and higher order interactions occurring within the mixture. An interaction-based hazard index was then calculated for each toxic effect by summing the ratio of AUCtt obtained during mixed exposure (predefined mixture) and single exposure (TLV). For the carcinogenic constituents of the mixture, an interaction-based response additivity approach was applied. This method consisted of adding the cancer risk for each constituent, calculated as the product of q*tissue dose and AUCtt. The AUCtt during mixture exposures was obtained using an interaction-based PBPK model. The approaches developed in the present study permit, for the first time, the consideration of the impact of multichemical pharmacokinetic interactions at a quantitative level in mixture risk assessments.
ACCESSION #
44406197

 

Related Articles

  • A Review of its Use in the Symptomatic Treatment of Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and Acute Gouty Arthritis. Croom, Katherine F.; Siddiqui, M. Asif A. // Drugs;2009, Vol. 69 Issue 11, p1513 

    Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, approved in Europe for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Etoricoxib provided similar symptomatic relief to nonselective NSAIDs in patients with these...

  • Biologically Motivated Quantitative Models and the Mixture Toxicity Problem. Conolly, Rory B. // Toxicological Sciences;Sep2001, Vol. 63 Issue 1, p1 

    The article highlighted in this issue is “A PBPK Modeling-Based Approach to Account for Interactions in the Health Risk Assessment of Chemical Mixtures” by Sami Haddad, Martin Béliveau, Robert Tardif, and Kannan Krishnan (pp. 125–131).

  • Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Schoemaker, Nadja E.; Mathät, Ron A.; Schäffski, Patrick; Rosing, Hilde; Schellens, Jan H.; Beijnen, Jos H. // Cancer Chemotherapy & Pharmacology;Dec2002, Vol. 50 Issue 6, p514 

    Purpose. Our aim was to develop an optimal sampling strategy for the description of the pharmacokinetics of rubitecan and its active metabolite 9-aminocamptothecin (9-AC) for use in phase II/III studies with oral rubitecan administered in a daily times five schedule. Methods. Concentration-time...

  • Pharmacokinetics, Metabolism, Biodistribution, Radiation Dosimetry, and Toxicology of F-Fluoroacetate (F-FACE) in Non-human Primates. Nishii, Ryuichi; Tong, William; Wendt, Richard; Soghomonyan, Suren; Mukhopadhyay, Uday; Balatoni, Julius; Mawlawi, Osama; Bidaut, Luc; Tinkey, Peggy; Borne, Agatha; Alauddin, Mian; Gonzalez-Lepera, Carlos; Yang, Bijun; Gelovani, Juri // Molecular Imaging & Biology;Apr2012, Vol. 14 Issue 2, p213 

    Introduction: To facilitate the clinical translation of F-fluoroacetate (F-FACE), the pharmacokinetics, biodistribution, radiolabeled metabolites, radiation dosimetry, and pharmacological safety of diagnostic doses of F-FACE were determined in non-human primates. Methods: F-FACE was synthesized...

  • Pharmacokinetics of amoxycillin in healthy pigs.  // Veterinary Record: Journal of the British Veterinary Association;5/15/2004, Vol. 154 Issue 20, p616 

    Focuses on the pharmacokinetics of amoxycillin in healthy pigs. Assessment of tissue elimination rate; Mean residence time in plasma; Maximum residual limit.

  • Global challenges in the risk assessment of nanomaterials: Relevance to South Africa. Gulumian, Mary; Kuempel, Eileen D.; Savolainen, Kai // South African Journal of Science;Sep/Oct2012, Vol. 108 Issue 9/10, p22 

    Internationally, there are efforts to develop standardised toxicity testing and risk assessment methods for engineered nanomsterials (ENMs). To this end, health risk assessments need to be conducted on ENIMs synthesised in South Africa. Country-specific risk characterisation requires specific...

  • Detection and Confirmation of Metabolites at Microdosing Levels using the New AB SCIEX QTRAP 5500 System. Seto, Carmai; AieIIo, Mauro // Applied Clinical Trials;Mar2009 Application Notebook, p9 

    The article focuses on the detection and verification of metabolites at microdosing levels through the use of the Applied Biosystems Group Inc.'s SCIEX QTRAP� 5500 System. It states that comprehensive detection and confirmation of metabolites can be attained at microdose levels, because of...

  • Pharmacokinetics and Metabolism of Toltrazuil and Its Major Metabolites after Oral Administration in Broilers. Myoung-Seok Kim; Byung-Kwon Park; Youn-Hwan Hwang; In-Bae Song; Tea-Won Kim; Jung-Hee Cho; Sung-Ho Ham; Jong-Hwan Lim; Hyo-In Yun // Journal of Poultry Science;2013, Vol. 50 Issue 3, p257 

    Toltrazuril is a symmetrical tiazinetrione compound. It is active against all intracellular developmental stages including those of schizogony and gametogony. In this study the disposition kinetics of toltrazuril (TZR) and its major metabolites (TZR-SO and TZR-SO2) in broiler chickens after...

  • Influence of dosage forms on pharmacokinetics of daidzein and its main metabolite daidzein-7- O-glucuronide in rats. Feng Qui; Xiao-yan Chen; Bo Song; Da-fang Zhong; Chang-xiao Liu // Acta Pharmacologica Sinica;Sep2005, Vol. 26 Issue 9, p1145 

    To investigate the influence of dosage forms on the pharmacokinetics of daidzein and its main metabolite daidzein-7- O-glucuronide in Wistar rats. After administration of two typical dosage forms (daidzein solution and suspension), the concentrations of daidzein and daidzein-7- O-glucuronide...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics